Neobe Therapeutics

While immunotherapies have revolutionized the treatment of cancer, the large majority of patients with solid tumours still do not respond to them. Neobe is developing a platform for the engineering of programmable live biotherapeutics, which can colonise solid tumours and remodel their local microenvironment. By removing barriers to immune infiltration in a safe and localised way, Neobe’s recombinant live biotherapeutics can potentially double the number of cancer patients that respond to existing immunotherapeutic strategies.

Meet CEO and Co Founder, Pedro Correa de Sampaio PhD, in our CEO Spotlight video below.